%0 Journal Article
%A Custodio, A
%A Jimenez-Fonseca, P
%A Carmona-Bayonas, A
%A Gomez, M J
%A Del Olmo-García, M I
%A Lorenzo, I
%A Díaz, J Á
%A Canal, N
%A De la Cruz, G
%A Villabona, C
%T Use of healthcare REsources and associated COsts in controlled versus uncontrolled carcinoid SYndrome in patients with neuroendocrine tumours: the RECOSY study.
%D 2021
%U http://hdl.handle.net/10668/17983
%X To report healthcare resource use and associated costs in controlled versus uncontrolled carcinoid syndrome (CS) in patients with neuroendocrine tumours. A cross-sectional, non-interventional multicentre study was conducted with retrospective data analysis. Resource use was compared between two patient groups: those with controlled CS (> 12 months with no uncontrolled CS episodes) and uncontrolled CS ( 12 months with no uncontrolled CS episodes) and uncontrolled CS ( Twenty-six university hospitals in Spain participated, between July 2017 and April 2018. 137 patients were enrolled; 104 were analysed (2 groups of 52). Patients with uncontrolled CS had 10 times more emergency department (ED) visits (mean 1.0 vs 0.10 visits; P = 0.0167), were more likely to have a hospital admission (40.4% vs 19.2%; P = 0.0116) and had longer hospital stays (mean 7.87 vs 2.10 days; P = 0.0178) than those with controlled CS. This corresponded to higher annual hospitalisation costs (mean €5511.59 vs €1457.22; P = 0.028) and ED costs (€161.25 vs €14.85; P = 0.0236). The mean annual total healthcare costs were 60.0% higher in patients with uncontrolled than controlled CS (P = NS). This study quantifies higher health resource use, and higher hospitalisation and ED costs in patients with uncontrolled CS. Better control of CS may result 3in lower medical costs.
%K Carcinoid syndrome
%K Costs
%K Neuroendocrine tumour
%K Resources
%K Somatostatin analogues
%~